[The role of chlorazepate dipotassium (Tranxilium) in the therapy of psychosomatic syndromes (author's transl)].
Divided into four groups according to different kind and cause of disorder, 240 patients showing psychosomatic disorders have been treated with chlorazepate dipotassium only or in combination with clomipramine and dihydroergotamine tartrate ambulant or in hospital, depending on the degree of severity of the disorder. With 101 clinically treated cases of cyclothymic depression good results were obtained with combined treatment with chlorazepate dipotassium while reducing the dose of the antidepressant. The same result was obtained with 63 patients suffering from severe neurasthenic exhaustion and 13 patients with general neurodystonic symptoms treated with chlorazepate dipotassium only. The combination of the usual dihydroergotamine tartrate medication with a chlorazepate dipotassium treatment over several months showed longlasting good therapeutic results, confirmed by follow-up examinations, in 31 out of 40 cases with migraine respectively vasomotor headache. In the other nine patients with migraine the complaints persisted only in rare instances.
D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001341:Autonomic Nervous System; D002986:Clinical Trials as Topic; D003009:Clorazepate Dipotassium / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy; D004341:Drug Evaluation; D006801:Humans; D005222:Mental Fatigue / Q000188:drug therapy; D008881:Migraine Disorders / Q000188:drug therapy; D011602:Psychophysiologic Disorders / Q000188:drug therapy*; D012019:Reflex Sympathetic Dystrophy / Q000188:drug therapy; D014653:Vascular Headaches / Q000188:drug therapy
D014151:Anti-Anxiety Agents; D003009:Clorazepate Dipotassium
Die Stellung von Dikalium-chlorazepat (Tranxilium) in der Therapie psychovegetativer Syndrome